ADAR anticorps (AA 151-250)

N° du produit ABIN678218

Détail du produit anti-ADAR anticorps

Antigène: ADAR (Adenosine Deaminase, RNA-Specific (ADAR))

Épitope: AA 151-250

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp ADAR est non-conjugé

Application: Western Blotting (WB), ELISA, Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Réactivité croisée: Humain

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human ADAR1

Isotype: IgG

Information d'application

Indications d'application: WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Date de péremption: 12 months

Détails sur ADAR

Antigène: ADAR (Adenosine Deaminase, RNA-Specific (ADAR))

Autre désignation: ADAR1 (ADAR Produits)

Synonymes: anticorps red1, anticorps drada, anticorps wu:fc22a02, anticorps adar1, anticorps dsRAD, anticorps dsRAD-1, anticorps ADAR, anticorps ADAR1, anticorps CG12598, anticorps Dmel\\CG12598, anticorps EG:BACN35H14.1, anticorps adar, anticorps adr, anticorps cg12598, anticorps dADAR, anticorps dAdar, anticorps hypnos-2, anticorps NV18763, anticorps AGS6, anticorps DRADA, anticorps DSH, anticorps DSRAD, anticorps G1P1, anticorps IFI-4, anticorps IFI4, anticorps K88DSRBP, anticorps P136, anticorps AV242451, anticorps Adar1, anticorps mZaADAR, anticorps adenosine deaminase, RNA-specific, anticorps adenosine deaminase, RNA-specific S homeolog, anticorps adenosine deaminase, RNA specific, anticorps Adenosine deaminase acting on RNA, anticorps adenosine deaminase acting on RNA, anticorps double-stranded RNA-specific editase 1, anticorps adar, anticorps adar.S, anticorps ADAR, anticorps Adar, anticorps CpipJ_CPIJ011849, anticorps LOC100114127

Sujet:

Synonyms: DSH, AGS6, G1P1, IFI4, P136, ADAR1, DRADA, DSRAD, IFI-4, K88DSRBP, Double-stranded RNA-specific adenosine deaminase, 136 kDa double-stranded RNA-binding protein, Interferon-inducible protein 4, ADAR

Background: Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins, pre-mRNA splicing by altering splice site recognition sequences, RNA stability by changing sequences involved in nuclease recognition, genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication, and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence.

ID gène: 103

UniProt: P55265

Pathways: Protein targeting to Nucleus